Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound.

Segarra S, Miró G, Montoya A, Pardo-Marín L, Teichenné J, Ferrer L, Cerón JJ.

Parasit Vectors. 2018 Feb 21;11(1):103. doi: 10.1186/s13071-018-2705-z.

2.

Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis.

Segarra S, Miró G, Montoya A, Pardo-Marín L, Boqué N, Ferrer L, Cerón J.

Vet Parasitol. 2017 May 30;239:50-56. doi: 10.1016/j.vetpar.2017.04.014. Epub 2017 Apr 23.

3.

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.

Lemesre JL, Holzmuller P, Gonçalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G.

Vaccine. 2007 May 22;25(21):4223-34. Epub 2007 Mar 15.

PMID:
17395339
4.

Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas.

Saridomichelakis MN, Mylonakis ME, Leontides LS, Billinis C, Koutinas AF, Galatos AD, Gouletsou P, Diakou A, Kontos VI.

Vet Parasitol. 2005 Jun 30;130(3-4):199-205.

PMID:
15905034
5.

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

Solano-Gallego L, Riera C, Roura X, Iniesta L, Gallego M, Valladares JE, Fisa R, Castillejo S, Alberola J, Ferrer L, Arboix M, Portús M.

Vet Parasitol. 2001 Apr 19;96(4):265-76.

PMID:
11267753
6.

Immunologic progression of canine leishmaniosis following vertical transmission in United States dogs.

Vida B, Toepp A, Schaut RG, Esch KJ, Juelsgaard R, Shimak RM, Petersen CA.

Vet Immunol Immunopathol. 2016 Jan;169:34-8. doi: 10.1016/j.vetimm.2015.11.008. Epub 2015 Dec 2.

7.

[Interpretation of laboratory data during cryptic leishmaniasis in dog].

Gravino AE.

Parassitologia. 2004 Jun;46(1-2):227-9. Italian.

PMID:
15305723
8.

Leishmania infantum-specific IFN-γ production in stimulated blood from dogs with clinical leishmaniosis at diagnosis and during treatment.

Martínez-Orellana P, Marí-Martorell D, Montserrat-Sangrà S, Ordeix L, Baneth G, Solano-Gallego L.

Vet Parasitol. 2017 Dec 15;248:39-47. doi: 10.1016/j.vetpar.2017.10.018. Epub 2017 Oct 29.

PMID:
29173539
9.

Total serum IgD from healthy and sick dogs with leishmaniosis.

Martínez-Orellana P, Maristany C, Baxarias M, Álvarez-Fernández A, Baldassarre A, Ordeix L, Solano-Gallego L.

Parasit Vectors. 2019 Mar 26;12(1):119. doi: 10.1186/s13071-019-3384-0.

10.

Early reduction of Leishmania infantum-specific antibodies and blood parasitemia during treatment in dogs with moderate or severe disease.

Solano-Gallego L, Di Filippo L, Ordeix L, Planellas M, Roura X, Altet L, Martínez-Orellana P, Montserrat S.

Parasit Vectors. 2016 May 10;9(1):235. doi: 10.1186/s13071-016-1519-0.

11.

Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates.

Grimaldi G Jr, Teva A, Dos-Santos CB, Santos FN, Pinto ID, Fux B, Leite GR, Falqueto A.

PLoS One. 2017 Sep 27;12(9):e0185438. doi: 10.1371/journal.pone.0185438. eCollection 2017.

12.

A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis.

Fernández Cotrina J, Iniesta V, Monroy I, Baz V, Hugnet C, Marañon F, Fabra M, Gómez-Nieto LC, Alonso C.

Vaccine. 2018 Apr 5;36(15):1972-1982. doi: 10.1016/j.vaccine.2018.02.111. Epub 2018 Mar 7.

13.

Feline leishmaniosis: Is the cat a small dog?

Pennisi MG, Persichetti MF.

Vet Parasitol. 2018 Feb 15;251:131-137. doi: 10.1016/j.vetpar.2018.01.012. Epub 2018 Feb 2. Review.

14.

A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area.

Sabaté D, Llinás J, Homedes J, Sust M, Ferrer L.

Prev Vet Med. 2014 Jul 1;115(1-2):56-63. doi: 10.1016/j.prevetmed.2014.03.010. Epub 2014 Mar 22.

PMID:
24698328
15.

The prevalence of canine Leishmania infantum infection in western China detected by PCR and serological tests.

Wang JY, Ha Y, Gao CH, Wang Y, Yang YT, Chen HT.

Parasit Vectors. 2011 May 9;4:69. doi: 10.1186/1756-3305-4-69.

16.

Cutaneous immune mechanisms in canine leishmaniosis due to Leishmania infantum.

Papadogiannakis EI, Koutinas AF.

Vet Immunol Immunopathol. 2015 Feb 15;163(3-4):94-102. doi: 10.1016/j.vetimm.2014.11.011. Epub 2014 Nov 20. Review.

PMID:
25555497
17.

Comorbid infections induce progression of visceral leishmaniasis.

Toepp AJ, Monteiro GRG, Coutinho JFV, Lima AL, Larson M, Wilson G, Grinnage-Pulley T, Bennett C, Mahachi K, Anderson B, Ozanne MV, Anderson M, Fowler H, Parrish M, Willardson K, Saucier J, Tyrell P, Palmer Z, Buch J, Chandrashekar R, Brown GD, Oleson JJ, Jeronimo SMB, Petersen CA.

Parasit Vectors. 2019 Jan 23;12(1):54. doi: 10.1186/s13071-019-3312-3.

18.

Infectivity of promastigotes and amastigotes of Leishmania infantum in a canine model for leishmaniosis.

Campino L, Santos-Gomes G, Riça Capela MJ, Cortes S, Abranches P.

Vet Parasitol. 2000 Oct 20;92(4):269-75.

PMID:
10996738
19.

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol.

Manna L, Corso R, Galiero G, Cerrone A, Muzj P, Gravino AE.

Parasit Vectors. 2015 May 28;8:289. doi: 10.1186/s13071-015-0896-0.

20.

First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Hernández L, Gálvez R, Montoya A, Checa R, Bello A, Bosschaerts T, Jansen H, Rupérez C, Fortin A, Miró G.

Parasitol Res. 2014 Jan;113(1):157-64. doi: 10.1007/s00436-013-3638-2. Epub 2013 Nov 6.

PMID:
24192865

Supplemental Content

Support Center